Figure 6From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatinCombined treatment with TRAIL receptor antibodies and cisplatin increases cell death. H28, ZL5, ZL55 and H226 cells were cultured with or without 2 μM cisplatin for 24 h. Cells were then left untreated or treated with 10 μg/ml Mapatumumab (Mapa) (A) or Lexatumumab (Lexa) (B) for 24 h. Lysates were analyzed by immunoblotting as described under material and methods.Back to article page